Jesus San Miguel

Jesus San Miguel

UNVERIFIED PROFILE

Are you Jesus San Miguel?   Register this Author

Register author
Jesus San Miguel

Jesus San Miguel

Publications by authors named "Jesus San Miguel"

Are you Jesus San Miguel?   Register this Author

100Publications

5515Reads

14Profile Views

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.

Clin Cancer Res 2019 May 28;25(10):3176-3187. Epub 2019 Jan 28.

Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1597DOI Listing
May 2019

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Blood 2019 May 28;133(18):1953-1963. Epub 2019 Feb 28.

Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-09-874396DOI Listing
May 2019

How deep is the myeloma iceberg?

Blood 2018 12;132(23):2424-2425

Clinica Universidad de Navarra.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-10-878637DOI Listing
December 2018

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

N Engl J Med 2018 11;379(19):1811-1822

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Karol Marcinkowski University of Medical Sciences, Poznań (D.D.), and Silesian Medical University, Katowice (S.G.) - both in Poland; University Hospital, Nantes (P.M.), and Centre Hospitalier Universitaire de Poitiers-La Milétrie, Poitiers (X.L.) - both in France; National Hospital Organization Disaster Medical Center (N.T.) and the Japanese Red Cross Medical Center (K.S.), Tokyo, and Ibaraki Prefectural Central Hospital, Kasama (M.H.) - all in Japan; Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal (R.L.); Heidelberg University Hospital, Heidelberg, Germany (M.S.R.); Dana-Farber Cancer Institute, Boston (P.G.R.); Bristol-Myers Squibb, Princeton, NJ (M.P.M., Y.-M.J., S.G.S., M.R., B.R.); and Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain (J.S.-M.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805762
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805762DOI Listing
November 2018

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

J Clin Oncol 2018 03 17;36(8):728-734. Epub 2018 Jan 17.

David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona, Spain; Mihaela Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo Clinic, Scottsdale, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.5032DOI Listing
March 2018

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

N Engl J Med 2018 02 12;378(6):518-528. Epub 2017 Dec 12.

From University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona (J.S.-M.) - both in Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center, Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center, Chicago (A.J.); Würzburg University Medical Center, Würzburg, Germany (S.K.); Université Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.); Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno, Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust, Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.) - both in the United Kingdom; the Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clínica de Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC, Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi, Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen Research and Development, Raritan, NJ (J.W., H.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1714678DOI Listing
February 2018

Management of multiple myeloma in the newly diagnosed patient.

Hematology Am Soc Hematol Educ Program 2017 12;2017(1):498-507

Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Navarra, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2017.1.498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142596PMC
December 2017

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.

J Clin Oncol 2017 Sep 12;35(25):2900-2910. Epub 2017 May 12.

Juan-Jose Lahuerta, Maria-Teresa Cedena, Joaquin Martinez-Lopez, and María-Luisa Martín-Ramos, Hospital 12 de Octubre, CIBERONC; Raquel de Paz, Hospital Universitario La Paz; Rafael Martinez, Hospital Clínico San Carlos; Adrian Alegre, Hospital Universitario La Princesa, Madrid; Bruno Paiva and Jesus F. San-Miguel, Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona; Laura Rosiñol, and Joan Blade, Hospital Clínic de Barcelona, Barcelona; Maria-Belen Vidriales, Noemi Puig, Norma C. Gutierrez, Alejandro Martin, and María-Victoria Mateos, Hospital Universitario de Salamanca Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBERONC; Alberto Orfao, Servicio General de Citometría-NUCLEOS, Centro de Investigación del Cancer (IBMCC-USAL, CSIC), IBSAL and Department of Medicine, Universidad de Salamanca, CIBERONC, Salamanca; Lourdes Cordón and Javier De la Rubia, Hospital Universitario y Politécnico La Fe; Ana-Isabel Teruel, Hospital Clínico de Valencia, Valencia; Albert Oriol, Hospital Germans Trias i Pujol, Badalona; María-Asunción Echeveste, Hospital de Donostia, San Sebastian; Felipe de Arriba, Hospital Morales Meseguer, Murcia; Miguel T. Hernandez, Hospital Universitario de Canarias, Tenerife; Luis Palomera, Hospital Universitario Lozano Blesa, Zaragoza, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.2517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568033PMC
September 2017

Multiple Myeloma Minimal Residual Disease.

Cancer Treat Res 2016;169:103-122

Centro de Investigacion Medica Aplicada (CIMA), Clinica Universidad de Navarra, IDISNA, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-40320-5_7DOI Listing
June 2017

Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group.

Med Clin (Barc) 2017 06 22;148(11):517-523. Epub 2017 Mar 22.

Grupo Español de Mieloma (GEM)/PETHEMA; Clínica Universidad de Navarra, Pamplona, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medcli.2017.02.012DOI Listing
June 2017

Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma.

Pharmacol Res 2017 03 21;117:185-191. Epub 2016 Nov 21.

Clínica Universidad de Navarra, Universidad de Navarra, CIMA, IDISNA, Av. de Pio XII, 36, 31008 Pamplona, Navarra, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2016.11.020DOI Listing
March 2017

Deacetylase inhibitors: an advance in myeloma therapy?

Expert Rev Hematol 2017 Mar 1;10(3):229-237. Epub 2017 Feb 1.

a Department of Hematologic Malignancies , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1280388DOI Listing
March 2017

Is immunotherapy here to stay in multiple myeloma?

Haematologica 2017 03 12;102(3):423-432. Epub 2017 Jan 12.

Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2016.152504DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394971PMC
March 2017

Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case.

Clin Case Rep 2016 12 11;4(12):1096-1100. Epub 2016 Oct 11.

Department of Dermatology Complejo Asistencial Universitario de Salamanca/Instituto de investigación biomédica de Salamanca (CAUSA/IBSAL) Salamanca Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134131PMC
December 2016

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

J Clin Oncol 2016 11;34(32):3921-3930

A. Keith Stewart, Mayo Clinic, Scottsdale, AZ; Meletios A. Dimopoulos, Alexandra Hospital, Athens, Greece; Tamás Masszi, St. István and St. László Hospital, Semmelweis University, Budapest, Hungary; Ivan Špička, General University Hospital in Prague, Prague; Roman Hájek, University Hospital Brno and University of Ostrava, Brno, Czech Republic; Albert Oriol, Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol; Laura Rosiñol, Hospital Clínic de Barcelona, Barcelona; Jesus F. San-Miguel, Clinica Universidad de Navarra/El Centro de Investigacíon Médica Aplicada, Instituto de Investigacíon Sanitaria de Navarra, Pamplona, Spain; David S. Siegel, John Theurer Cancer Center at Hackensack University, Hackensack, NJ; Ruben Niesvizky, Weill Cornell Medical College, New York, NY; Andrzej J. Jakubowiak, University of Chicago Medicine, Chicago, IL; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilheminenspital, Vienna, Austria; Jacqui Buchanan, Xinqun Yang, Biao Xing, Naseem Zojwalla, and Margaret Tonda, Onyx Pharmaceuticals, South San Francisco, CA; Kim Cocks, KCStats Consultancy, Leeds, United Kingdom; Philippe Moreau, University of Nantes, Nantes, France; and Antonio Palumbo, University of Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.9648DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791840PMC
November 2016

Utility of flow cytometry studies in the management of patients with multiple myeloma.

Curr Opin Oncol 2016 11;28(6):511-517

Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000331DOI Listing
November 2016

Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.

Br J Haematol 2016 Nov 19;175(3):448-456. Epub 2016 Jul 19.

Clinical and Translational Medicine, Clínica Universidad de Navarra - CIMA (Centro de Investigación Médica Aplicada) - IdiSNA (Instituto de Investigación Sanitaria de Navarra), Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14263DOI Listing
November 2016

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 10;375(14):1319-1331

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona (A.O.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); Tom Baker Cancer Centre, University of Calgary, Calgary, AB (N.J.B.), and the Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto (D.R.) - both in Canada; Levine Cancer Institute-Carolinas HealthCare System, Charlotte, NC (S.Z.U.); the Department of Haematology, University College London Hospitals NHS Trust, London (N.R.); the Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); the Department of Hematology and Stem Cell Transplantation, Poznan University of Medical Sciences, Poznan, Poland (M.K.); the Department of Hematology, Japanese Red Cross Medical Center, Tokyo (K.S.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.), and Genmab, Copenhagen (S.L.) - both in Denmark; the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); the Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem (D.B.Y.); Dana-Farber Cancer Institute, Harvard Medical School, Boston (P.G.R.); University Hospital Heidelberg and the German Cancer Research Center, Heidelberg, Germany (H.G.); Janssen Research and Development, Spring House, PA (N.Z.K., L.O., C.C., X.Q., M.G., T.A.); and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France (P.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1607751DOI Listing
October 2016

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

Clin Cancer Res 2016 Aug 22;22(16):4206-4214. Epub 2016 Mar 22.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987182PMC
August 2016

Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma.

Am J Pathol 2016 08 11;186(8):2171-2182. Epub 2016 Jun 11.

Hematology Department, University Hospital of Salamanca, Biomedical Research Institute of Salamanca, Salamanca, Spain; Cancer Research Center, University of Salamanca, Salamanca, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2016.04.003DOI Listing
August 2016

Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.

Expert Rev Clin Pharmacol 2016 26;9(1):35-48. Epub 2015 Oct 26.

d CIMA, IDISNA , Clínica Universidad de Navarra , Pamplona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17512433.2016.1096773DOI Listing
June 2016

Origin of Waldenstrom's macroglobulinaemia.

Best Pract Res Clin Haematol 2016 06 6;29(2):136-147. Epub 2016 Oct 6.

Servicio General de Citometría de la Universidad de Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2016.08.024DOI Listing
June 2016

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.

J Clin Oncol 2016 05 14;34(13):1544-57. Epub 2016 Mar 14.

Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0044DOI Listing
May 2016

Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.

Clin Cancer Res 2016 Jan 4;22(1):207-17. Epub 2015 Sep 4.

Centro de Investigacion del Cancer-IBMCC (USAL-CSIC), Salamanca, Spain. Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. Servicio de Hematología, Hospital Universitario, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2796DOI Listing
January 2016

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.

Biol Blood Marrow Transplant 2015 Dec 30;21(12):2039-2051. Epub 2015 Sep 30.

University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.09.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757494PMC
December 2015

Treatment for patients with newly diagnosed multiple myeloma in 2015.

Blood Rev 2015 Nov 12;29(6):387-403. Epub 2015 Jun 12.

Clínica Universidad de Navarra/Centro de Investigación Médica Aplicada (CIMA), Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2015.06.001DOI Listing
November 2015

Panobinostat for the Treatment of Multiple Myeloma.

Clin Cancer Res 2015 Nov 11;21(21):4767-73. Epub 2015 Sep 11.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0530DOI Listing
November 2015

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

J Clin Oncol 2015 Sep 3;33(26):2863-9. Epub 2015 Aug 3.

Antonio Palumbo, Stefania Oliva, Simona Caltagirone, Sara Bringhen, and Francesca Gay, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute della Salute e della Scienza di Torino; Roberto Passera, University of Torino, Torino; Massimo Offidani, Clinica di Ematologia, AUO Ospedali Riuniti di Ancona, Ancona; Pellegrino Musto, Istituto di Ricovero e Cura a Carattere Scientifico, Referral Cancer Center of Basilicata, Rionero in Vulture; Maria T. Petrucci, Sapienza University of Rome, Rome; Elena Zamagni and Michele Cavo, Istituto di Ematologia Seragnoli, Università di Bologna, Bologna, Italy; Hervé Avet-Loiseau and Michel Attal, Institut Claudius Regaud, L'Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse; Thierry Facon, Service des Maladies du Sang, Hôpital Claude Huriez, Centre Hospitalier Regionale et Universitaire Lille, Lille; Philippe Moreau, University Hospital Hotel-Dieu, Nantes, France; Henk M. Lokhorst, VU University Medical Center, Amsterdam; Pieter Sonneveld, Erasmus MC, Rotterdam, the Netherlands; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg, Germany; Laura Rosinol, Hospital Clínic, Institut Clínic d'Investigacions Biomèdiques Ausgust Pi i Sunyer, Barcelona; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid; Jésus San Miguel, Clínica Universidad de Navarra, Centro de Investigaciones Médicas Aplicadas, IDISNA, Pamplona, Spain; Paul Richardson and Kenneth C. Anderson, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA; Shaji Kumar and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Sagar Lonial, Winship Cancer Institute, Emory University, Atlanta, GA; Robert Z. Orlowski, The University of Texas MD Anderson Comprehensive Cancer Center, Houston, TX; Gareth Morgan, Myeloma Institutes for Research Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; Brian G.M. Durie, Cedars-Sinai Comprehensive Canc

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/08/03/JCO.2015.61
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.61.2267
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.61.2267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846284PMC
September 2015

Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells.

Cancer Cell 2015 Sep;28(3):281-3

Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, 31008 Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2015.08.009DOI Listing
September 2015

Guidelines for determination of the number of prior lines of therapy in multiple myeloma.

Blood 2015 Aug;126(7):921-2

Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-05-647636DOI Listing
August 2015